Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247739 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
A Phase 2 study, sponsored by Pharming Technologies B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02247739: Completed Phase 2 study, sponsored by Pharming Technologies B.V..
NCT02247739 is a Phase 2 study that has completed, run by Pharming Technologies B.V.. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02247739, a Phase 2 study, has completed, sponsored by Pharming Technologies B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE Secondary Objective: To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE
Primary Outcome
Average number of HAE attacks normalized to a 28 day period
Interventions
- OTHER Placebo
- BIOLOGICAL Recombinant human C1 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT02247739 record still lists
NCT02247739 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02247739 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02247739 about?
NCT02247739 is a clinical study titled "A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor". Primary Objective: To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE Secondary Objective: To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks...
What is the current status of trial NCT02247739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02247739?
The interventions under investigation include: Placebo (OTHER), Recombinant human C1 inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT02247739?
This trial is sponsored by Pharming Technologies B.V., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02247739's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia